introduction

1
Kidney International, Vol. 63, Supplement 84 (2003), p. S1 Introduction It is our privilege and pleasure to present in this Kidney The articles nicely reflect the forum for the invaluable International supplement the proceedings of the Interna- exchange of recent scientific thoughts and experiences tional Congress on Uremic Toxicity, held in the stimulat- in the broad spectrum of preclinical and clinical topics ing historic atmosphere of Wu ¨ rzburg, Germany, Septem- related to uremia and the cardiovascular system that this ber 13–16, 2002. congress provided. It, therefore, made a great impact on More than 250 participants from around the world took those who attended to promote new scientific research part in this fruitful meeting, focusing on novel aspects of and therapeutic approaches for the understanding and uremia and the cardiovascular system. The aim of this treatment of uremic conditions. Congress was to provide up-to-date information about We would like to thank all of the speakers and authors major advances in the understanding and treatment of for their contributions. We sincerely hope that this Sup- uremia-associated conditions and their cardiovascular plement allows those who were not able to participate consequences. This supplement contains articles drawn in the Congress to share the novel and insightful ideas from the lectures presented and discussed in the produc- that were presented. tive atmosphere of the congress venue, including the Publication of this Supplement was made possible following topics: the relevance of uremic toxicity; oxida- by generous grants from Baxter Healthcare Corpora- tive stress and nitric oxide (NO); endothelial dysfunction; tion, Fresenius Medical Care, Gambro Medizintechnik the role of inflammation; cytokines and the immune sys- GmbH, OrthoBiotech Division of Janssen Cilag GmbH, tem; metabolism and inflammation; the impact of dyslipi- and Pfizer GmbH. demias; the importance of homocysteine; carbonyl stress and advanced glycation end products (AGEs); uremia, Thomas Quaschning and Christoph Wanner Guest Editors genes, and the heart; and epidemiology and clinical trials. 2003 by the International Society of Nephrology S-1

Upload: christoph

Post on 06-Jul-2016

212 views

Category:

Documents


0 download

TRANSCRIPT

Kidney International, Vol. 63, Supplement 84 (2003), p. S1

Introduction

It is our privilege and pleasure to present in this Kidney The articles nicely reflect the forum for the invaluableInternational supplement the proceedings of the Interna- exchange of recent scientific thoughts and experiencestional Congress on Uremic Toxicity, held in the stimulat- in the broad spectrum of preclinical and clinical topicsing historic atmosphere of Wurzburg, Germany, Septem- related to uremia and the cardiovascular system that thisber 13–16, 2002. congress provided. It, therefore, made a great impact on

More than 250 participants from around the world took those who attended to promote new scientific researchpart in this fruitful meeting, focusing on novel aspects of and therapeutic approaches for the understanding anduremia and the cardiovascular system. The aim of this treatment of uremic conditions.Congress was to provide up-to-date information about We would like to thank all of the speakers and authorsmajor advances in the understanding and treatment of for their contributions. We sincerely hope that this Sup-uremia-associated conditions and their cardiovascular plement allows those who were not able to participateconsequences. This supplement contains articles drawn in the Congress to share the novel and insightful ideasfrom the lectures presented and discussed in the produc- that were presented.tive atmosphere of the congress venue, including the Publication of this Supplement was made possiblefollowing topics: the relevance of uremic toxicity; oxida- by generous grants from Baxter Healthcare Corpora-tive stress and nitric oxide (NO); endothelial dysfunction; tion, Fresenius Medical Care, Gambro Medizintechnikthe role of inflammation; cytokines and the immune sys- GmbH, OrthoBiotech Division of Janssen Cilag GmbH,tem; metabolism and inflammation; the impact of dyslipi- and Pfizer GmbH.demias; the importance of homocysteine; carbonyl stressand advanced glycation end products (AGEs); uremia, Thomas Quaschning and Christoph Wanner

Guest Editorsgenes, and the heart; and epidemiology and clinical trials.

2003 by the International Society of Nephrology

S-1